Brainomix Secures Additional $25.4 Million for U.S. Expansion of AI Imaging Solutions

Brainomix Expands Funding for U.S. Growth

Brainomix, an innovator in AI-powered imaging solutions for stroke and lung fibrosis, has successfully secured an additional £4.8 million (approximately $6.5 million) in a Series C funding extension. This investment increases the total funding in this round to a remarkable £18.8 million (around $25.4 million), which is poised to accelerate the company's growth within the U.S. healthcare market.

With its headquarters in Oxford, England, and additional offices in the USA and Ireland, Brainomix is recognized for its pioneering efforts in developing advanced imaging tools that aid in clinical decision-making. The newly raised funds will enhance the company’s existing portfolio of FDA-cleared AI imaging solutions, specifically its Brainomix 360 Stroke and e-Lung platforms, which are designed for acute stroke assessment and monitoring of pulmonary fibrosis, respectively.

The funding extension was primarily driven by existing investors Parkwalk Advisors and Hostplus, who are part of the IP Group Hostplus Innovation Fund, alongside the addition of new U.S. investor Modi Ventures. According to Dr. Michalis Papadakis, CEO and co-founder of Brainomix, this investment reflects strong confidence in their technology and highlights the positive impact of their platforms on patient care. He stated, "This investment extension positions us well to enhance customer support across the U.S. and Europe, accelerating the integration of our technology in clinical workflows and broadening access to treatment."

The necessity for rapid care in stroke cases is critical, and the Brainomix 360 Stroke is engineered to provide healthcare professionals with timely tools for better treatment decision-making. This automated platform integrates AI technology to ensure high accuracy in assessments, ultimately leading to improved patient outcomes.

Moreover, the e-Lung AI imaging technology is being deployed to identify and track progression in patients suffering from fibrosing lung disease. By early detection and consistent monitoring, Brainomix aims to facilitate timely treatment options that can significantly alter patient outcomes. Sahir Ali, founder of Modi Ventures, remarked on the importance of Brainomix’s comprehensive approach: "With rigorous clinical validation and evidence supporting our technology, Brainomix has built a robust platform."

Founded as a spinout from the University of Oxford, Brainomix continues to evolve within the healthcare landscape, providing cutting-edge solutions that enhance patient care. Their products are now utilized in over 20 countries, showcasing their commitment to improving healthcare outcomes through AI-driven innovation. As they seek to expand their footprint in the U.S. market, the future looks promising for Brainomix and the patients benefiting from this transformative technology.

To learn more about Brainomix and its innovative technology offerings, visit their official website at www.brainomix.com.